NTRK1 and lung cancer: Li and colleagues reported that dasatinib binds and targets SFK members as well as a panel of receptor tyrosine kinases (EGFR, ephrin receptors, DDR1) and non-receptor tyrosine kinases (FRK, BRK, ACK) in lung cancer [14].